tert-butyl 3-(3-oxo-1-piperidinyl)propanoate | 891858-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 3-(3-oxo-1-piperidinyl)propanoate
• 英文别名: tert-butyl 3-(3-oxopiperidin-1-yl)propanoate
• CAS: 891858-62-1
• 化学式: C₁₂H₂₁NO₃
• 分子量: 227.304
• InChiKey: AITNVIDRRUUOCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-(3-oxo-1-piperidinyl)propanoate 在 sodium hydride 作用下， 以 二甲基亚砜 为溶剂， 反应 18.5h， 生成 tert-butyl 3-{3-[4-(3-phenylpropoxy)benzylidene]-1-piperidinyl}propanoate
  参考文献：
  名称：

  WO2006/64757

  摘要：

  公开号：
• 作为产物：
  描述：

  Tert-butyl 3-(3-hydroxypiperidin-1-yl)propanoate 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 tert-butyl 3-(3-oxo-1-piperidinyl)propanoate
  参考文献：
  名称：

  Structure–activity relationship studies of sphingosine-1-phosphate receptor agonists with N-cinnamyl-β-alanine moiety

  摘要：

  Structure-activity relationship of sphingosine-1-phosphate receptor agonist was examined. In terms of reducing the flexibility of molecule, hit compound 1 was modified to improve S1P(1) agonistic activity as well as selectivity over S1P(3) agonistic activity. Novel S1P agonists with cinnamyl scaffold or 1,2,5,6-tetrahydropyridine scaffold were identified. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.029

文献信息

• AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF
  申请人：Habashita Hiromu

  公开号：US20090275554A1

  公开（公告）日：2009-11-05

  The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. wherein all symbols are described in the specification.

  本发明涉及一种由公式（I）表示的化合物，其盐，其N-氧化物形式，其溶剂化物或其前药，以及含有该化合物的药物。公式（I）表示的化合物具有结合S1P受体（特别是EDG-1，EDG-6和/或EDG-8）的能力，可用于预防和/或治疗移植排斥，移植物抗宿主病，自身免疫性疾病，过敏性疾病，神经退行性疾病等。其中所有符号在说明书中描述。
• Aminocarboxylic acid derivative and medicinal use thereof
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US07906549B2

  公开（公告）日：2011-03-15

  The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. wherein all symbols are described in the specification.

  本发明涉及一个由公式（I）表示的化合物，其盐，N-氧化物形式，溶剂合物或前药，以及含有该化合物的药物。由公式（I）表示的化合物具有结合S1P受体（特别是EDG-1，EDG-6和/或EDG-8）的能力，并可用于预防和/或治疗移植排斥反应，移植物抗宿主病，自身免疫性疾病，过敏性疾病，神经退行性疾病等。其中所有符号均在说明书中描述。
• Azetidinecarboxylic acid derivative and medicinal use thereof
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP2371811A2

  公开（公告）日：2011-10-05

  A compound represented by the formula (IC-2), a salt thereof, an N-oxide form thereof, a solvate thereof, a prodrug thereof, or a number of specific compounds and pharmaceutical compositions comprising these compounds. The compound has the ability to combine with an SIP receptor (especially EDG-1, EDG-6 and/or EDG-8). It is useful for the prevention and/or treatment of rejection reactions to transplantation, graft versus host diseases, autoimmune diseases, allergic diseases, neurodegenerative diseases etc.

  由式（IC-2）代表的化合物、其盐、其 N-氧化物形式、其溶液剂、其原药或一些特定化合物以及包含这些化合物的药物组合物。该化合物具有与 SIP 受体（尤其是 EDG-1、EDG-6 和/或 EDG-8）结合的能力。它可用于预防和/或治疗移植排斥反应、移植物抗宿主疾病、自身免疫性疾病、过敏性疾病、神经退行性疾病等。
• Aminocarboxylic acid derivative and medical use thereof
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP2592066A1

  公开（公告）日：2013-05-15

  The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. wherein all symbols are described in the specification.

  本发明涉及一种由式（I）代表的化合物、其盐、其N-氧化物形式、其溶液或其原药，以及含有该化合物的药物。式（I）代表的化合物具有与S1P受体（特别是EDG-1、EDG-6和/或EDG-8）结合的能力，可用于预防和/或治疗移植排斥反应、移植物抗宿主疾病、自身免疫性疾病、过敏性疾病、神经变性疾病等。 其中所有符号在说明书中均有描述。
• US7906549B2
  申请人：——

  公开号：US7906549B2

  公开（公告）日：2011-03-15